XP
X4 Pharmaceuticals, Inc
SEC filingBiotechnology · Boston, MA
Amount raised$85Msold at filing
Total offering$85M
Investors in the raise18count reported to the SEC
FiledAug 25, 2025first sale Aug 13, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Mary DiBiaseExecutive Officer
Murray W. StewartDirector
Christophe Arbet-EngelsExecutive Officer
David KirskeExecutive Officer
Michael S. WyzgaDirector
John VolponeExecutive Officer
Mark BaldryExecutive Officer
Francoise J. De CraeckerDirector
Gary J. BridgerDirector
Adam CraigExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.